Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.

ABSTRACT:

Abstract

Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor (CAR)-modified T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or use intensive at-home monitoring. We report outcomes of outpatient administration of all commercially available CD19- and B-cell maturation antigen (BCMA)-directed CAR T-cell therapy using a strategy of no remote at-home monitoring and an early cytokine release syndrome (CRS) intervention strategy. Patients with hematologic malignancies who received CAR T-cell therapy in the outpatient setting during 2022 to 2023 were included. Patients were seen daily in the cancer center day hospital for the first 7 to 10 days and then twice weekly through day 30. The primary end point was to det

SUBMITTER: Furqan F 

PROVIDER: S-EPMC11372811 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature